Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
Published in: | ESMO Open |
---|---|
Main Authors: | , , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Elsevier BV
2017
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/esmoopen-2017-000222 https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/plain https://syndication.highwire.org/content/doi/10.1136/esmoopen-2017-000222 |
Description not available. |